Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates

Core Insights - Arcellx, Inc. reported quarterly earnings of $0.42 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.63 per share, and improving from a loss of $0.76 per share a year ago [1] - The company achieved revenues of $63.15 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 163.52%, compared to zero revenues a year ago [1] Financial Performance - The earnings surprise for the recent quarter was 166.67%, while the previous quarter saw a loss of $0.81 per share against an expected loss of $0.56, resulting in a surprise of -44.64% [1] - Over the last four quarters, Arcellx has exceeded consensus EPS estimates two times [1] Stock Performance - Arcellx shares have increased by approximately 21.8% since the beginning of the year, outperforming the S&P 500's gain of 6.5% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of $20.95 million, and for the current fiscal year, it is -$2.13 on revenues of $107.66 million [4] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [4] Industry Context - Cardiff Oncology, another company in the same industry, is expected to report a quarterly loss of $0.26 per share, with revenues projected at $0.08 million, reflecting a year-over-year decline of 42.3% [5]